Bioventus (BVS) Set to Announce Quarterly Earnings on Tuesday

Bioventus (NYSE:BVS) is set to release its earnings data before the market opens on Tuesday, November 5th. Analysts expect Bioventus to post earnings of $0.06 per share for the quarter. Bioventus has set its FY 2024 guidance at 0.360-0.420 EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Bioventus (NYSE:BVS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.12. The firm had revenue of $151.22 million for the quarter, compared to the consensus estimate of $137.70 million. Bioventus had a negative net margin of 7.82% and a positive return on equity of 14.39%. During the same period last year, the firm posted $0.14 earnings per share. On average, analysts expect Bioventus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Bioventus Stock Performance

NYSE:BVS opened at $13.58 on Friday. The company’s 50-day moving average price is $11.58 and its 200-day moving average price is $8.17. The company has a current ratio of 1.33, a quick ratio of 0.96 and a debt-to-equity ratio of 1.82. The company has a market cap of $1.10 billion, a P/E ratio of -20.58 and a beta of 0.88. Bioventus has a twelve month low of $3.36 and a twelve month high of $14.00.

Insider Buying and Selling

In other news, Director John A. Bartholdson acquired 80,000 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average cost of $8.55 per share, for a total transaction of $684,000.00. Following the completion of the transaction, the director now owns 6,913,857 shares in the company, valued at approximately $59,113,477.35. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, Director John A. Bartholdson purchased 80,000 shares of the company’s stock in a transaction on Friday, August 16th. The stock was acquired at an average cost of $8.55 per share, for a total transaction of $684,000.00. Following the completion of the transaction, the director now directly owns 6,913,857 shares in the company, valued at approximately $59,113,477.35. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director John A. Bartholdson purchased 25,500 shares of the company’s stock in a transaction on Monday, August 19th. The shares were bought at an average price of $8.55 per share, with a total value of $218,025.00. Following the completion of the transaction, the director now owns 6,939,357 shares of the company’s stock, valued at approximately $59,331,502.35. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 32.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on BVS. Canaccord Genuity Group raised their price objective on shares of Bioventus from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, August 13th. Craig Hallum raised their price objective on shares of Bioventus from $12.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, September 27th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.